Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A.
He joins Opus from Remix Therapeutics, where he served as Chief Financial Officer and led the company’s finance function, strategic financing process, fundraising efforts and IPO preparation. Previously, he served as Chief Financial Officer and Chief Business Officer at Verastem Oncology, where he oversaw finance, business development, and investor relations and led capital raising efforts. He has also held senior finance leadership roles at Harvard Bioscience, Clean Harbors, and Biogen, and began his career in audit and advisory services at Deloitte and PricewaterhouseCoopers.
Mr. Gagnon holds an MBA from the MIT Sloan School of Management, a BA in Accounting from Bentley College, and is a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology, Harvard Bioscience, Purple Biotech and Bone Biologics.
What is Robert E. Gagnon's net worth?
The estimated net worth of Robert E. Gagnon is at least $3.03 million as of April 23rd, 2026. Gagnon owns 592,158 shares of Opus Genetics stock worth more than $3,025,927 as of April 30th. This net worth estimate does not reflect any other assets that Gagnon may own. Learn More about Robert E. Gagnon's net worth.
How do I contact Robert E. Gagnon?
Has Robert E. Gagnon been buying or selling shares of Opus Genetics?
Over the course of the past ninety days, Robert E. Gagnon has sold $40,621.56 in shares of Opus Genetics stock. Most recently, Robert E. Gagnon sold 7,842 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.18, for a transaction totalling $40,621.56. Following the completion of the sale, the chief financial officer now directly owns 592,158 shares of the company's stock, valued at $3,067,378.44. Learn More on Robert E. Gagnon's trading history.
Who are Opus Genetics' active insiders?
Are insiders buying or selling shares of Opus Genetics?
During the last year, Opus Genetics insiders bought shares 2 times. They purchased a total of 164,000 shares worth more than $323,890.00. During the last year, insiders at the sold shares 11 times. They sold a total of 4,073,395 shares worth more than $8,982,278.31. The most recent insider tranaction occured on April, 23rd when President Benjamin R Yerxa sold 7,470 shares worth more than $39,142.80. Insiders at Opus Genetics own 11.7% of the company.
Learn More about insider trades at Opus Genetics. Information on this page was last updated on 4/23/2026.
